|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US20180147202A1
(en)
|
2015-06-05 |
2018-05-31 |
Arvinas, Inc. |
TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
US20180072711A1
(en)
|
2016-09-15 |
2018-03-15 |
Arvinas, Inc. |
Indole derivatives as estrogen receptor degraders
|
|
CA3041840A1
(en)
|
2016-10-28 |
2018-05-03 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for treating ezh2-mediated cancer
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
RS64976B1
(sr)
|
2016-12-01 |
2024-01-31 |
Arvinas Operations Inc |
Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
RU2019121527A
(ru)
|
2016-12-23 |
2021-01-15 |
Эрвинэс Оперейшнс, Инк. |
Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
JP7679173B2
(ja)
|
2016-12-23 |
2025-05-19 |
アルビナス・オペレーションズ・インコーポレイテッド |
Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
CN117551089A
(zh)
|
2017-01-26 |
2024-02-13 |
阿尔维纳斯运营股份有限公司 |
雌激素受体蛋白水解调节剂及相关使用方法
|
|
CA3050309A1
(en)
|
2017-01-31 |
2018-08-09 |
Arvinas Operations, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
KR102014478B1
(ko)
*
|
2017-05-12 |
2019-08-26 |
한국화학연구원 |
신규한 피페리딘-2,6-디온 유도체 및 이의 용도
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
SG11202000143PA
(en)
|
2017-07-10 |
2020-02-27 |
Celgene Corp |
Antiproliferative compounds and methods of use thereof
|
|
WO2019043217A1
(en)
|
2017-09-04 |
2019-03-07 |
F. Hoffmann-La Roche Ag |
DIHYDROBENZIMIDAZOLONES
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
CN111278815B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
戊二酰亚胺
|
|
CA3076613A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2019060693A1
(en)
*
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES THEREOF
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
EP3737675A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
EP3743066A4
(en)
|
2018-01-26 |
2021-09-08 |
Yale University |
IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE
|
|
US11028088B2
(en)
|
2018-03-10 |
2021-06-08 |
Yale University |
Modulators of BTK proteolysis and methods of use
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
JP7252973B2
(ja)
|
2018-03-26 |
2023-04-05 |
ノバルティス アーゲー |
Ｎ－（３－（７Ｈ－ピロロ［２，３－ｄ］ピリミジン－４－イル）フェニル）ベンズアミド誘導体
|
|
FI3774789T3
(fi)
|
2018-04-01 |
2025-06-17 |
Arvinas Operations Inc |
Brm:ään kohdentuvia yhdisteitä ja niihin liittyviä käyttömenetelmiä
|
|
JP7720698B2
(ja)
|
2018-04-04 |
2025-08-08 |
アルビナス・オペレーションズ・インコーポレイテッド |
タンパク質分解の調節因子および関連する使用方法
|
|
JP2021521192A
(ja)
*
|
2018-04-13 |
2021-08-26 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
セレブロンリガンドおよび同リガンドを含む二機能性化合物
|
|
EP3781156A4
(en)
|
2018-04-16 |
2022-05-18 |
C4 Therapeutics, Inc. |
SPIROCYCLIC COMPOUNDS
|
|
US11358952B2
(en)
|
2018-04-23 |
2022-06-14 |
Celgene Corporation |
Substituted 4-aminoisoindoline-1,3-dione compounds, compositions thereof, and methods of treatment therewith
|
|
CN112566666A
(zh)
|
2018-05-14 |
2021-03-26 |
努瓦申生物公司 |
靶向抗癌核激素受体的化合物
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CA3102217A1
(en)
|
2018-06-29 |
2020-01-02 |
Dana-Farber Cancer Institute, Inc. |
Bispecific degraders
|
|
US12234220B2
(en)
|
2018-06-29 |
2025-02-25 |
Dana-Farber Cancer Institute, Inc. |
Immunomodulatory compounds
|
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
PL3820573T3
(pl)
|
2018-07-10 |
2024-02-19 |
Novartis Ag |
Pochodne 3-(5-hydroksy-1-oksoizoindolin-2-ylo)piperydyno-2,6-dionu i ich zastosowanie w leczeniu chorób zależnych od palca cynkowego z rodziny ikaros 2 (ikzf2)
|
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
|
WO2020023851A1
(en)
|
2018-07-26 |
2020-01-30 |
Yale University |
Bifunctional substitued pyrimidines as modulators of fak proteolyse
|
|
JP7515175B2
(ja)
|
2018-07-31 |
2024-07-12 |
ファイメクス株式会社 |
複素環化合物
|
|
CN108774215A
(zh)
*
|
2018-08-15 |
2018-11-09 |
翟学旭 |
含氮杂环类衍生物及其在视网膜新生血管疾病中的应用
|
|
JP7297053B2
(ja)
|
2018-08-20 |
2023-06-23 |
アルビナス・オペレーションズ・インコーポレイテッド |
神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
|
|
US11969472B2
(en)
|
2018-08-22 |
2024-04-30 |
Cullgen (Shanghai), Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
CN112888681B
(zh)
|
2018-08-22 |
2025-11-18 |
上海睿跃生物科技有限公司 |
原肌球蛋白受体激酶(trk)降解化合物及使用方法
|
|
EP3846800A4
(en)
|
2018-09-04 |
2022-08-24 |
C4 Therapeutics, Inc. |
Compounds for the degradation of brd9 or mth1
|
|
WO2020048547A1
(zh)
*
|
2018-09-07 |
2020-03-12 |
南京明德新药研发有限公司 |
三环并呋喃取代哌啶二酮类化合物
|
|
JP7623943B2
(ja)
|
2018-11-30 |
2025-01-29 |
カイメラ セラピューティクス， インコーポレイテッド |
Ｉｒａｋ分解剤およびそれらの使用
|
|
EP3890736A4
(en)
*
|
2018-12-03 |
2022-08-10 |
Dana Farber Cancer Institute, Inc. |
HELIOS SMALL MOLECULE DEGRADERS AND METHOD OF USE
|
|
BR112021011968A2
(pt)
|
2018-12-19 |
2021-09-08 |
Celgene Corporation |
Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos
|
|
TW202039434A
(zh)
|
2018-12-19 |
2020-11-01 |
美商西建公司 |
經取代之3-((3-胺基苯基)胺基)哌啶-2,6-二酮化合物、其組合物及使用彼等之治療方法
|
|
CN120698985A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
EP3917916A4
(en)
*
|
2019-01-30 |
2022-12-14 |
Montelino Therapeutics, Inc. |
Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
|
|
US20220105188A1
(en)
*
|
2019-02-07 |
2022-04-07 |
Korea Research Institute Of Chemical Technology |
Target protein eed degradation-inducing degraducer, preparation method thereof, and pharmaceutical composition for preventing or treating diseases related to eed, ezh2, or prc2, comprising same as active ingredient
|
|
EP3924055B1
(en)
|
2019-02-15 |
2024-04-03 |
Novartis AG |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
|
US20220143183A1
(en)
*
|
2019-02-23 |
2022-05-12 |
New York University |
Photoswitchable protacs and synthesis and uses thereof
|
|
MX2021012216A
(es)
|
2019-04-05 |
2022-01-24 |
Kymera Therapeutics Inc |
Degradadores de transductores de señal y activadores de transcripción (stat) y usos de los mismos.
|
|
WO2020206608A1
(en)
*
|
2019-04-09 |
2020-10-15 |
Ranok Therapeutics (Hangzhou) Co., Ltd. |
Methods and compositions for targeted protein degradation
|
|
US12414995B2
(en)
|
2019-04-16 |
2025-09-16 |
Northwestern University |
Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer
|
|
BR112021020775A2
(pt)
*
|
2019-04-18 |
2021-12-14 |
Hinova Pharmaceuticals Inc |
Classe de compostos heterocíclicos quiméricos bifuncionais para a degradação direcionada de receptores de andrógeno e uso dos mesmos
|
|
CN114423463B
(zh)
*
|
2019-05-06 |
2025-09-26 |
西奈山伊坎医学院 |
作为hpk1的降解剂的异双功能化合物
|
|
AU2020274113A1
(en)
|
2019-05-14 |
2021-11-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2020251969A1
(en)
*
|
2019-06-10 |
2020-12-17 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2020252397A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Baylor College Of Medicine |
Small molecule proteolysis-targeting chimeras and methods of use thereof
|
|
JP7295283B2
(ja)
|
2019-06-25 |
2023-06-20 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｌｔ３ｌ－ｆｃ融合タンパク質及び使用方法
|
|
CN114867727B
(zh)
*
|
2019-07-17 |
2025-02-21 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
KR20220054347A
(ko)
*
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
CN114641337A
(zh)
*
|
2019-08-27 |
2022-06-17 |
密歇根大学董事会 |
Cereblon e3连接酶抑制剂
|
|
EP4043455A4
(en)
*
|
2019-09-12 |
2023-09-20 |
Medshine Discovery Inc. |
BICYCLIC COMPOUND THAT ACTS AS A REGULATOR OF CRBN PROTEIN
|
|
EP4031243A1
(en)
*
|
2019-09-16 |
2022-07-27 |
Novartis AG |
Glue degraders and methods of use thereof
|
|
JP2022547952A
(ja)
*
|
2019-09-16 |
2022-11-16 |
ノバルティス アーゲー |
Ｂｒｄ９二機能性分解誘導薬及びその使用方法
|
|
WO2021067606A1
(en)
|
2019-10-01 |
2021-04-08 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
CA3154386A1
(en)
|
2019-10-17 |
2021-04-22 |
Michael Berlin |
Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
CN110885332B
(zh)
*
|
2019-12-06 |
2022-03-18 |
中国人民解放军第二军医大学 |
一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用
|
|
GB201918414D0
(en)
|
2019-12-13 |
2020-01-29 |
Z Factor Ltd |
Compounds and their use for the treatment of Alpha1-Antitrypsin deficiency
|
|
US11591332B2
(en)
|
2019-12-17 |
2023-02-28 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
|
EP4076001A4
(en)
*
|
2019-12-17 |
2023-12-20 |
Orionis Biosciences, Inc. |
MODULATION OF PROTEIN DEGRADATION
|
|
KR20220145325A
(ko)
|
2019-12-17 |
2022-10-28 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
|
CR20220353A
(es)
|
2019-12-19 |
2022-10-20 |
Arvinas Operations Inc |
Compuestos y métodos para la degradación dirigida del receptor de andrógenos
|
|
PE20221724A1
(es)
|
2019-12-20 |
2022-11-04 |
C4 Therapeutics Inc |
Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr)
|
|
MX2022007885A
(es)
|
2019-12-23 |
2022-09-19 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Metodo y aplicacion de preparacion de compuesto como agente de degradacion de proteinas.
|
|
WO2021133920A1
(en)
|
2019-12-23 |
2021-07-01 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021146386A1
(en)
*
|
2020-01-14 |
2021-07-22 |
The Trustees Of Columbia University In The City Of New York |
Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases
|
|
TW202140475A
(zh)
*
|
2020-01-16 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
|
|
TW202140448A
(zh)
*
|
2020-01-16 |
2021-11-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
|
|
US11618751B1
(en)
|
2022-03-25 |
2023-04-04 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
|
|
TWI832035B
(zh)
|
2020-02-14 |
2024-02-11 |
美商基利科學股份有限公司 |
結合ccr8之抗體及融合蛋白及其用途
|
|
WO2023205701A1
(en)
|
2022-04-20 |
2023-10-26 |
Kumquat Biosciences Inc. |
Macrocyclic heterocycles and uses thereof
|
|
AU2021225981A1
(en)
|
2020-02-26 |
2022-09-29 |
Cullgen (Shanghai) , Inc. |
Tropomyosin receptor kinase (TRK) degradation compounds and methods of use
|
|
EP3875456A1
(en)
*
|
2020-03-02 |
2021-09-08 |
Technische Universität Darmstadt |
Hetero-bifunctional proteolysis-targeting chimeras (protacs) for the selective degradation of fk506-binding proteins (fkbps)
|
|
WO2021178920A1
(en)
|
2020-03-05 |
2021-09-10 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of brd9
|
|
CN111249276B
(zh)
*
|
2020-03-05 |
2021-07-13 |
南京巴傲得生物科技有限公司 |
吲哚布洛芬制备cbp溴区抑制试剂的用途
|
|
AU2021229979A1
(en)
*
|
2020-03-06 |
2022-10-27 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on CRBN protein and preparation method therefor
|
|
CN113387931A
(zh)
*
|
2020-03-13 |
2021-09-14 |
四川海思科制药有限公司 |
一种具有抑制或降解蛋白激酶的化合物及其制备方法和药学上的应用
|
|
CN115380026B
(zh)
*
|
2020-03-17 |
2023-11-07 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
CA3171337A1
(en)
*
|
2020-03-18 |
2021-09-23 |
Dana-Farber Cancer Institute, Inc. |
Targeted degraders of aberrant tau based on the pet tracer pbb3
|
|
WO2021188948A1
(en)
|
2020-03-19 |
2021-09-23 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
WO2021194318A1
(en)
*
|
2020-03-27 |
2021-09-30 |
Uppthera |
Plk1 selective degradation inducing compound
|
|
WO2021210878A1
(ko)
*
|
2020-04-17 |
2021-10-21 |
광주과학기술원 |
Crbn 결합 펩티드 및 이를 이용한 알츠하이머 병 예방 또는 치료용 조성물
|
|
US20240270780A1
(en)
*
|
2020-04-29 |
2024-08-15 |
Tai Bi Di Pharmaceutical Technology (Shijiazhuang) Co. Ltd |
Proteolysis targeting compound with tissue targeting capability and use thereof
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
WO2021231927A1
(en)
*
|
2020-05-14 |
2021-11-18 |
The Regents Of The University Of Michigan |
Androgen receptor protein degraders with a tricyclic cereblon ligand
|
|
WO2021236885A1
(en)
*
|
2020-05-21 |
2021-11-25 |
Dana-Farber Cancer Institute, Inc. |
Piperidine-2,6-diones as small molecule degraders of helios and methods of use
|
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
|
IL298962A
(en)
|
2020-06-12 |
2023-02-01 |
Shanghai Jemincare Pharmaceuticals Co Ltd |
Phthalazinone compound, its preparation method and its medical use
|
|
US20230234957A1
(en)
*
|
2020-06-22 |
2023-07-27 |
Dana-Farber Cancer Institute, Inc. |
Protein tag to induce ligand dependent degradation of protein/protein-fusions
|
|
KR102559329B1
(ko)
*
|
2020-07-02 |
2023-07-25 |
포항공과대학교 산학협력단 |
신규한 프로탁 키메라 화합물, 이를 포함하는 표적 단백질 분해를 통한 질환의 예방, 개선 또는 치료용 약학적 조성물
|
|
CN115697992B
(zh)
*
|
2020-07-09 |
2025-09-19 |
西藏海思科制药有限公司 |
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
|
|
AU2021311245A1
(en)
*
|
2020-07-21 |
2023-03-09 |
Ubix Therapeutics, Inc. |
Compound for androgen receptor degradation, and pharmaceutical use thereof
|
|
KR20220014952A
(ko)
*
|
2020-07-29 |
2022-02-08 |
한국화학연구원 |
안드로겐 수용체의 저해 또는 분해용 화합물 및 이들의 의약 용도
|
|
CA3186919A1
(en)
*
|
2020-08-03 |
2022-02-10 |
Sylvain Cottens |
Low molecular weight protein degraders and their applications
|
|
IL300397A
(en)
|
2020-08-05 |
2023-04-01 |
C4 Therapeutics Inc |
Compounds for targeted knockdown of RET
|
|
TWI833104B
(zh)
*
|
2020-08-05 |
2024-02-21 |
大陸商上海領泰生物醫藥科技有限公司 |
靶向蛋白降解化合物及其製備方法和應用
|
|
US12180193B2
(en)
|
2020-08-28 |
2024-12-31 |
Arvinas Operations, Inc. |
Accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
CN114133379B
(zh)
*
|
2020-09-04 |
2024-02-13 |
南京奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114163444B
(zh)
*
|
2020-09-11 |
2023-07-14 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
JP2023541434A
(ja)
|
2020-09-14 |
2023-10-02 |
アルビナス・オペレーションズ・インコーポレイテッド |
エストロゲン受容体の標的化分解のための化合物の結晶性形態
|
|
CN114181277A
(zh)
*
|
2020-09-15 |
2022-03-15 |
江苏恒瑞医药股份有限公司 |
一种用于雄激素受体蛋白靶向降解的嵌合体化合物、其制备方法及其在医药上的应用
|
|
MX2023003114A
(es)
|
2020-09-23 |
2023-03-23 |
St Jude Childrens Res Hospital Inc |
Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon.
|
|
KR20230079408A
(ko)
|
2020-09-30 |
2023-06-07 |
아스트라제네카 아베 |
화합물 및 암의 치료에서의 이의 용도
|
|
AU2021360596A1
(en)
*
|
2020-10-14 |
2023-06-08 |
C4 Therapeutics, Inc. |
Tricyclic compounds to degrade neosubstrates for medical therapy
|
|
WO2022087125A1
(en)
|
2020-10-21 |
2022-04-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor protein
|
|
CN114621231B
(zh)
*
|
2020-12-14 |
2025-09-12 |
杭州中美华东制药有限公司 |
一种靶向降解/抑制活性的嵌合化合物及其制备方法和用途
|
|
AR124547A1
(es)
|
2020-12-30 |
2023-04-05 |
Kymera Therapeutics Inc |
Degradadores de irak y sus usos
|
|
CA3208313A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
EP4289841A4
(en)
*
|
2021-02-04 |
2025-02-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
US11773103B2
(en)
|
2021-02-15 |
2023-10-03 |
Kymera Therapeutics, Inc. |
IRAK4 degraders and uses thereof
|
|
MX2023009527A
(es)
|
2021-02-15 |
2023-08-24 |
Kymera Therapeutics Inc |
Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
|
|
US20240383868A1
(en)
*
|
2021-02-19 |
2024-11-21 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
JP2024509625A
(ja)
*
|
2021-03-15 |
2024-03-04 |
ノバルティス アーゲー |
ベンゾイソオキサゾール誘導体及びその使用
|
|
JP2024510792A
(ja)
|
2021-03-23 |
2024-03-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
CA3211378A1
(en)
*
|
2021-03-29 |
2022-10-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
|
|
CA3211149A1
(en)
*
|
2021-03-31 |
2022-10-06 |
Phillip Martin Cowley |
Pharmaceutical compound
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US11319319B1
(en)
|
2021-04-07 |
2022-05-03 |
Ventus Therapeutics U.S., Inc. |
Compounds for inhibiting NLRP3 and uses thereof
|
|
AU2022259683A1
(en)
|
2021-04-16 |
2023-10-19 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
CN113603676B
(zh)
*
|
2021-04-28 |
2022-05-24 |
浙江工业大学 |
基于厄洛替尼靶向降解egfr蛋白小分子化合物及其制备方法和应用
|
|
JP2024516024A
(ja)
*
|
2021-05-03 |
2024-04-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
AR125768A1
(es)
|
2021-05-05 |
2023-08-09 |
Biogen Ma Inc |
Compuestos para la degradación dirigida de la tirosina cinasa de bruton
|
|
AR125798A1
(es)
|
2021-05-07 |
2023-08-16 |
Kymera Therapeutics Inc |
Degradadores cdk2 y usos de los mismos
|
|
WO2022245671A1
(en)
|
2021-05-18 |
2022-11-24 |
Gilead Sciences, Inc. |
Methods of using flt3l-fc fusion proteins
|
|
US12384756B2
(en)
*
|
2021-05-26 |
2025-08-12 |
Innocure Therapeutics, Inc. |
Piperidinedione derivatives
|
|
WO2022250350A1
(ko)
*
|
2021-05-26 |
2022-12-01 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102489160B1
(ko)
*
|
2021-05-26 |
2023-01-18 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
KR102474999B1
(ko)
*
|
2021-05-26 |
2022-12-07 |
주식회사 이노큐어테라퓨틱스 |
피페리딘디온 유도체
|
|
WO2022255889A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255888A1
(en)
*
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
MX2023014059A
(es)
|
2021-06-08 |
2024-03-12 |
C4 Therapeutics Inc |
Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
|
|
CN117715903A
(zh)
*
|
2021-06-25 |
2024-03-15 |
新基公司 |
Cereblon结合化合物、其组合物及其用于治疗的方法
|
|
EP4359407A4
(en)
*
|
2021-06-25 |
2025-04-30 |
Celgene Corporation |
CEREBLON-BINDING COMPOUNDS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT USING THEM
|
|
JP2024526192A
(ja)
*
|
2021-06-25 |
2024-07-17 |
セルジーン コーポレーション |
セレブロン結合化合物、その組成物及びそれによる治療方法
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
EP4366834A1
(en)
|
2021-07-07 |
2024-05-15 |
Biogen MA Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
TW202321236A
(zh)
|
2021-07-07 |
2023-06-01 |
美商百健Ｍａ公司 |
用於靶向ｉｒａｋ４蛋白降解之化合物
|
|
AU2022306297A1
(en)
|
2021-07-09 |
2024-02-08 |
Plexium, Inc. |
Aryl compounds and pharmaceutical compositions that modulate ikzf2
|
|
JP2024530495A
(ja)
*
|
2021-08-10 |
2024-08-21 |
オップテラ インコーポレイテッド |
新規ｐｌｋ１分解誘導化合物
|
|
TW202321219A
(zh)
*
|
2021-08-11 |
2023-06-01 |
大陸商四川海思科製藥有限公司 |
雜環衍生物及其組合物和藥學上的應用
|
|
DK4367118T3
(da)
|
2021-08-18 |
2025-03-24 |
Nurix Therapeutics Inc |
Bifunktionelle nedbrydere af interleukin-1-receptor-associerede kinaser og terapeutisk brug heraf
|
|
EP4393922A1
(en)
*
|
2021-08-23 |
2024-07-03 |
Shanghai Leadingtac Pharmaceutical Co. Ltd. |
Irak4 degradation agent, and preparation method therefor and use thereof
|
|
WO2023034411A1
(en)
|
2021-09-01 |
2023-03-09 |
Oerth Bio Llc |
Compositions and methods for targeted degradation of proteins in a plant cell
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
WO2023056443A1
(en)
*
|
2021-10-01 |
2023-04-06 |
Dana-Farber Cancer Institute, Inc. |
Binders of cereblon and methods of use thereof
|
|
WO2023059792A1
(en)
*
|
2021-10-06 |
2023-04-13 |
C4 Thrapeutics, Inc. |
Coronavirus non-structural protein 3 degrading compounds
|
|
KR20240110576A
(ko)
*
|
2021-10-22 |
2024-07-15 |
글루탁스 테라퓨틱스 (상하이) 씨오., 엘티디. |
Crbn e3 리가제 리간드 화합물, 리간드 화합물에 기초하여 개발된 단백질 분해제 및 이들의 응용
|
|
WO2023076983A1
(en)
|
2021-10-28 |
2023-05-04 |
Gilead Sciences, Inc. |
Pyridizin-3(2h)-one derivatives
|
|
JP7787991B2
(ja)
|
2021-10-29 |
2025-12-17 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｃｄ７３化合物
|
|
EP4422635A4
(en)
|
2021-10-29 |
2025-11-26 |
Kymera Therapeutics Inc |
IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
|
|
WO2023081224A1
(en)
*
|
2021-11-03 |
2023-05-11 |
St. Jude Children's Research Hospital, Inc. |
Substituted n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4- yl)methyl)benzamide analogs as modulators of cereblon protein
|
|
WO2023081452A1
(en)
*
|
2021-11-05 |
2023-05-11 |
University Of South Carolina |
Small-molecule degraders of cdk8 and cdk19
|
|
US20250064945A1
(en)
|
2021-11-24 |
2025-02-27 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
WO2023097031A1
(en)
|
2021-11-24 |
2023-06-01 |
Arvinas Operations, Inc. |
Brm targeting compounds and associated methods of use
|
|
JP2024543129A
(ja)
|
2021-11-25 |
2024-11-19 |
江蘇恒瑞医薬股▲ふん▼有限公司 |
アンドロゲン受容体タンパク質の標的分解のためのキメラ化合物、その調製方法及びその医薬的使用
|
|
AU2022419982A1
(en)
|
2021-12-22 |
2024-06-06 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
WO2023122615A1
(en)
|
2021-12-22 |
2023-06-29 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
TW202340168A
(zh)
|
2022-01-28 |
2023-10-16 |
美商基利科學股份有限公司 |
Ｐａｒｐ７抑制劑
|
|
CA3243560A1
(en)
|
2022-01-31 |
2023-08-03 |
Kymera Therapeutics, Inc. |
Iraqi Degradation Agents and Their Uses
|
|
TW202346277A
(zh)
|
2022-03-17 |
2023-12-01 |
美商基利科學股份有限公司 |
Ｉｋａｒｏｓ鋅指家族降解劑及其用途
|
|
CN119301111A
(zh)
*
|
2022-03-24 |
2025-01-10 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为protac中的降解决定子的2,4-二氧代四氢嘧啶基衍生物
|
|
PE20250157A1
(es)
|
2022-04-21 |
2025-01-22 |
Gilead Sciences Inc |
Compuestos de modulacion de kras g12d
|
|
WO2023212599A2
(en)
*
|
2022-04-26 |
2023-11-02 |
Endotarget Inc. |
Compounds and methods for targeted degradation of estrogen receptors
|
|
CN119325475A
(zh)
|
2022-06-06 |
2025-01-17 |
C4医药公司 |
双环取代的戊二酰亚胺cereblon结合剂
|
|
WO2024002205A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related disease by using the same
|
|
CN119384415A
(zh)
|
2022-07-01 |
2025-01-28 |
吉利德科学公司 |
Cd73化合物
|
|
WO2024015412A1
(en)
*
|
2022-07-12 |
2024-01-18 |
Regents Of The University Of Michigan |
Tetrahydronaphthalene derivatives as estrogen receptor degraders
|
|
CN116496253B
(zh)
*
|
2022-08-19 |
2024-10-11 |
中国人民解放军军事科学院军事医学研究院 |
c-MET蛋白靶向降解剂及其医药应用
|
|
CN115089588A
(zh)
*
|
2022-08-22 |
2022-09-23 |
云南大学 |
达沙布韦作为e3连接酶新型配体构建protac的应用
|
|
WO2024050016A1
(en)
|
2022-08-31 |
2024-03-07 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|
|
WO2024054954A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024051766A1
(zh)
*
|
2022-09-08 |
2024-03-14 |
标新生物医药科技(上海)有限公司 |
基于cereblon蛋白设计的分子胶化合物及其应用
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
WO2024054953A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
CA3267079A1
(en)
|
2022-09-09 |
2024-03-14 |
Innovo Therapeutics, Inc. |
CK1α AND DOUBLE CK1α/GSPT1 DEGRADATION COMPOUNDS
|
|
CN119855812A
(zh)
*
|
2022-09-14 |
2025-04-18 |
海南先声再明医药股份有限公司 |
多并环类化合物及其用途
|
|
WO2024064316A1
(en)
|
2022-09-23 |
2024-03-28 |
Regents Of The University Of Michigan |
Compounds and compositions as smarca2/4 inhibitors and uses thereof
|
|
WO2024073475A1
(en)
*
|
2022-09-27 |
2024-04-04 |
Oncopia Therapeutics, Inc. D/B/A Proteovant Therapeutics, Inc. |
Cereblon ligands and uses thereof
|
|
EP4596538A1
(en)
*
|
2022-09-29 |
2025-08-06 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method
|
|
CN119998300A
(zh)
*
|
2022-09-29 |
2025-05-13 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
EP4608404A1
(en)
|
2022-10-24 |
2025-09-03 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
US12331048B2
(en)
|
2022-10-31 |
2025-06-17 |
Ventus Therapeutics U.S., Inc. |
Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
|
|
CN120603823A
(zh)
*
|
2022-11-22 |
2025-09-05 |
因诺库尔治疗公司 |
用于分解cMET蛋白的降解剂和包含其的药物组合物
|
|
CN120584116A
(zh)
*
|
2022-11-22 |
2025-09-02 |
因诺库尔治疗公司 |
用于使brd蛋白降解的降解剂和含有其的药物组合物
|
|
EP4624472A1
(en)
*
|
2022-11-22 |
2025-10-01 |
Innocure Therapeutics, Inc. |
Degrader including novel c-met protein ligand and pharmaceutical composition including same
|
|
AU2023389065A1
(en)
*
|
2022-12-06 |
2025-06-19 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
WO2024123195A1
(en)
*
|
2022-12-06 |
2024-06-13 |
Captor Therapeutics S.A. |
Targeted protein degradation using prodrugs of bifunctional compounds that bind ubiquitin ligase and target mcl-1 protein
|
|
US20240254118A1
(en)
|
2022-12-22 |
2024-08-01 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
CN120615091A
(zh)
*
|
2023-01-16 |
2025-09-09 |
正大天晴药业集团股份有限公司 |
取代的苯并七元环化合物及其应用
|
|
KR20250151412A
(ko)
|
2023-01-26 |
2025-10-21 |
아비나스 오퍼레이션스, 인코포레이티드 |
세레블론계 kras 분해 단백질 및 이와 관련된 용도
|
|
KR20250145679A
(ko)
*
|
2023-02-16 |
2025-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
Ret 키나제의 분해제로서의 이소인돌리논 글루타르이미드 및 페닐 글루타르이미드 유사체
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
TW202508568A
(zh)
|
2023-04-07 |
2025-03-01 |
瑞典商阿斯特捷利康公司 |
Ｉｒａｋ４蛋白水解靶向嵌合體
|
|
KR20250167002A
(ko)
|
2023-04-11 |
2025-11-28 |
길리애드 사이언시즈, 인코포레이티드 |
Kras 조절 화합물
|
|
AU2024256729A1
(en)
*
|
2023-04-20 |
2025-09-25 |
Auron Therapeutics, Inc. |
Technologies targeting cell states
|
|
CN121079300A
(zh)
|
2023-04-21 |
2025-12-05 |
吉利德科学公司 |
Prmt5抑制剂及其用途
|
|
CN120981456A
(zh)
|
2023-05-24 |
2025-11-18 |
金橘生物科技公司 |
杂环化合物及其用途
|
|
WO2024245444A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
标新生物医药科技(上海)有限公司 |
氧代异吲哚啉基取代的四氢嘧啶二酮衍生物及其应用
|
|
CN120202200A
(zh)
*
|
2023-06-01 |
2025-06-24 |
标新生物医药科技(上海)有限公司 |
基于氧代异吲哚啉基取代的四氢嘧啶二酮的化合物及其应用
|
|
WO2024245408A1
(zh)
*
|
2023-06-01 |
2024-12-05 |
上海海和药物研究开发股份有限公司 |
用于雄激素受体依赖性疾病的苯并(杂)环烷基化合物
|
|
WO2024256988A1
(en)
|
2023-06-14 |
2024-12-19 |
Astrazeneca Ab |
Smarca2 degraders and uses thereof
|
|
WO2024257012A1
(en)
|
2023-06-14 |
2024-12-19 |
Astrazeneca Ab |
3-[3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl]-3,8-diazabicyclo[3.2.1]octane derivatives as smarca2 degrading protacs for the treatment of cancer
|
|
WO2024263781A1
(en)
*
|
2023-06-23 |
2024-12-26 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Targeted degraders of hiv-1 nef for the treatment of hiv disease
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
US20250042922A1
(en)
|
2023-06-30 |
2025-02-06 |
Gilead Sciences, Inc. |
Kras modulating compounds
|
|
WO2025006783A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
WO2025007000A1
(en)
|
2023-06-30 |
2025-01-02 |
Kumquat Biosciences Inc. |
Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
|
|
WO2025011623A1
(zh)
*
|
2023-07-12 |
2025-01-16 |
上海壹迪生物技术有限公司 |
氰基喹啉类靶向蛋白降解分子、其制备方法和应用
|
|
US20250066328A1
(en)
|
2023-07-26 |
2025-02-27 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025024811A1
(en)
|
2023-07-26 |
2025-01-30 |
Gilead Sciences, Inc. |
Parp7 inhibitors
|
|
WO2025049555A1
(en)
|
2023-08-31 |
2025-03-06 |
Oerth Bio Llc |
Compositions and methods for targeted inhibition and degradation of proteins in an insect cell
|
|
WO2025054530A1
(en)
|
2023-09-08 |
2025-03-13 |
Gilead Sciences, Inc. |
Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
|
|
US20250101042A1
(en)
|
2023-09-08 |
2025-03-27 |
Gilead Sciences, Inc. |
Kras g12d modulating compounds
|
|
WO2025056074A1
(zh)
*
|
2023-09-14 |
2025-03-20 |
中国科学院上海药物研究所 |
杂环基取代的吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
WO2025063888A1
(en)
|
2023-09-19 |
2025-03-27 |
Kancure Pte. Ltd. |
Survivin-targeted compounds
|
|
AR133886A1
(es)
*
|
2023-09-22 |
2025-11-12 |
Glaxosmithkline Ip Dev Ltd |
Compuestos novedosos
|
|
WO2025075693A1
(en)
*
|
2023-10-02 |
2025-04-10 |
Purdue Research Foundation |
Shp2 degraders for cancer therapy
|
|
WO2025096855A1
(en)
|
2023-11-02 |
2025-05-08 |
Kumquat Biosciences Inc. |
Degraders and uses thereof
|
|
WO2025096589A1
(en)
|
2023-11-03 |
2025-05-08 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|
|
US20250177539A1
(en)
*
|
2023-12-01 |
2025-06-05 |
Astrazeneca Ab |
Er degraders and uses thereof
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
WO2025137640A1
(en)
|
2023-12-22 |
2025-06-26 |
Gilead Sciences, Inc. |
Azaspiro wrn inhibitors
|
|
WO2025179161A1
(en)
|
2024-02-21 |
2025-08-28 |
Innovo Therapeutics, Inc. |
Protein degrading compounds
|
|
WO2025212557A1
(en)
*
|
2024-04-01 |
2025-10-09 |
The Johns Hopkins University |
Delivery of aurora kinase inhibitors using nano-scale drug delivery platforms by covalent conjugation
|
|
WO2025245003A1
(en)
|
2024-05-21 |
2025-11-27 |
Gilead Sciences, Inc. |
Prmt5 inhibitors and uses thereof
|